Reply to ‘Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab'

類似資料

• Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
  著者:: Papakostas, T D, 等
  出版事項: (2016)
• Comment on: ‘Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'
  著者:: Călugăru, D, 等
  出版事項: (2016)
• Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
  著者:: Wang, Jia-Kang, 等
  出版事項: (2016)
• Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion‐related macular oedema: A prospective randomized comparison—Comment
  著者:: Wen, Dejia, 等
  出版事項: (2019)
• Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
  著者:: Hykin, Philip, 等
  出版事項: (2021)